DK3484880T3 - Heteroaromatiske modulatorer af retinoid-relateret orphan receptor gamma - Google Patents

Heteroaromatiske modulatorer af retinoid-relateret orphan receptor gamma Download PDF

Info

Publication number
DK3484880T3
DK3484880T3 DK17737284.4T DK17737284T DK3484880T3 DK 3484880 T3 DK3484880 T3 DK 3484880T3 DK 17737284 T DK17737284 T DK 17737284T DK 3484880 T3 DK3484880 T3 DK 3484880T3
Authority
DK
Denmark
Prior art keywords
orphane
retinoid
heteroaromatic
modulators
receptor gamma
Prior art date
Application number
DK17737284.4T
Other languages
Danish (da)
English (en)
Inventor
Alan Stuart Jessiman
Patrick Stephen Johnson
Kristoffer Maansson
Morten Dahl Sørensen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Application granted granted Critical
Publication of DK3484880T3 publication Critical patent/DK3484880T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
DK17737284.4T 2016-07-13 2017-07-11 Heteroaromatiske modulatorer af retinoid-relateret orphan receptor gamma DK3484880T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16020268 2016-07-13
PCT/EP2017/067390 WO2018011201A1 (en) 2016-07-13 2017-07-11 Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Publications (1)

Publication Number Publication Date
DK3484880T3 true DK3484880T3 (da) 2020-11-09

Family

ID=56511303

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17737284.4T DK3484880T3 (da) 2016-07-13 2017-07-11 Heteroaromatiske modulatorer af retinoid-relateret orphan receptor gamma

Country Status (21)

Country Link
US (2) US10662181B2 (enExample)
EP (1) EP3484880B1 (enExample)
JP (1) JP7016344B2 (enExample)
KR (1) KR102490140B1 (enExample)
CN (1) CN109476653B (enExample)
AU (1) AU2017294969B2 (enExample)
BR (1) BR112019000486A2 (enExample)
CA (1) CA3030370A1 (enExample)
DK (1) DK3484880T3 (enExample)
ES (1) ES2834009T3 (enExample)
IL (1) IL264141B (enExample)
MX (1) MX383770B (enExample)
MY (1) MY196990A (enExample)
PL (1) PL3484880T3 (enExample)
PT (1) PT3484880T (enExample)
RU (1) RU2771280C2 (enExample)
SA (1) SA519400868B1 (enExample)
SG (1) SG11201811107WA (enExample)
UA (1) UA123330C2 (enExample)
WO (1) WO2018011201A1 (enExample)
ZA (1) ZA201808436B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019000486A2 (pt) * 2016-07-13 2019-04-24 Leo Pharma A/S composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase
CN111825654A (zh) * 2019-04-19 2020-10-27 北京酷瓴生物技术有限公司 苯甲烯哌啶衍生物及其制备方法、中间体和用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS244821B2 (en) 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
FR2879381B1 (fr) 2004-12-15 2008-12-26 Thales Sa Systeme de distribution quantique de cle de cryptage a variables continues
UA95071C2 (ru) * 2005-04-04 2011-07-11 Аб Сьянс Замещенные производные оксазола и их применение как ингибиторов тирозинкиназы
EP2511275A1 (en) * 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
PE20151144A1 (es) 2012-12-06 2015-08-02 Glaxo Group Ltd Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias
CA2929194A1 (en) 2013-11-05 2015-05-14 F. Hoffmann-La Roche Ag 5,6,7,8-tetrahydro-5,8-methanocinnoline derivatives as rorc modulators for the treatment of autoimmune diseases
KR20170012388A (ko) 2014-05-28 2017-02-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 신규 화합물
JP6759110B2 (ja) * 2014-05-28 2020-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 新規な化合物
ES2716966T3 (es) 2014-05-28 2019-06-18 Glaxosmithkline Ip Dev Ltd Derivados de piperazina como moduladores de ROR-gamma
BR112019000486A2 (pt) * 2016-07-13 2019-04-24 Leo Pharma A/S composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase

Also Published As

Publication number Publication date
MX383770B (es) 2025-03-14
NZ749301A (en) 2021-03-26
US10934282B2 (en) 2021-03-02
RU2019103883A (ru) 2020-08-13
AU2017294969A1 (en) 2019-01-17
BR112019000486A2 (pt) 2019-04-24
EP3484880B1 (en) 2020-09-02
IL264141A (en) 2019-02-28
CN109476653A (zh) 2019-03-15
RU2019103883A3 (enExample) 2020-09-23
US20190284177A1 (en) 2019-09-19
KR20190026872A (ko) 2019-03-13
PT3484880T (pt) 2020-12-07
US10662181B2 (en) 2020-05-26
SA519400868B1 (ar) 2022-06-13
WO2018011201A1 (en) 2018-01-18
CN109476653B (zh) 2022-04-22
JP7016344B2 (ja) 2022-02-04
PL3484880T3 (pl) 2021-04-06
JP2019521137A (ja) 2019-07-25
MX2019000361A (es) 2019-05-23
EP3484880A1 (en) 2019-05-22
UA123330C2 (uk) 2021-03-17
US20200291010A1 (en) 2020-09-17
ES2834009T3 (es) 2021-06-16
SG11201811107WA (en) 2019-01-30
MY196990A (en) 2023-05-17
AU2017294969B2 (en) 2021-03-25
RU2771280C2 (ru) 2022-04-29
IL264141B (en) 2021-09-30
ZA201808436B (en) 2020-05-27
CA3030370A1 (en) 2018-01-18
KR102490140B1 (ko) 2023-01-19

Similar Documents

Publication Publication Date Title
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
SI3743406T1 (sl) Modulatorji TMEM16A
DK3433234T3 (da) Allosteriske modulatorer af nicotinacetylcholinreceptorer
DK3331876T3 (da) Modulators of ror-gamma
DK3515600T3 (da) Array af organoider
EP3423033A4 (en) SELF-EMULSIFYING COMPOSITIONS OF CB2 RECEPTOR MODULATORS
EP3383386A4 (en) MODULATORS OF CHEMOKIN RECEPTORS
HUE054009T2 (hu) Szubsztituált tetrahidrokinolinon vegyületek ROR gamma modulátorként
DK3300500T3 (da) Triazolagonister af apj-receptoren
EP3442971C0 (en) ESTROGEN RECEPTOR MODULATORS
DK3207043T6 (da) Dihydropyrrolopyridin-inhibitorer af ror-gamma
LT3322701T (lt) Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai
DK3160964T3 (da) Arylreceptormodulatorer og fremgangsmåder til fremstilling og brug af samme
IL283967A (en) Modulators of hsd17b13 expression
IL281492A (en) Modulators of pnpla3 expression
DK3157929T3 (da) Pyrazolforbindelser som modulatorer af fshr og anvendelser deraf
HUE048902T2 (hu) Új ROR gamma modulátor vegyületek
IL268731A (en) New uses of anti-sirpg antibodies
DK3364958T3 (da) Modulatorer af sestrin-gator2-interaktion og anvendelser deraf
DK2964229T3 (da) Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren
DK3389692T3 (da) Modulatorer af komplement-aktivitet
BR112017026561A2 (pt) moduladores alostéricos positivos do receptor muscarínico m2
DK3104847T3 (da) Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser
DK3544416T3 (da) Applikation af væsker
HRP20190024T1 (hr) Derivati hidroksialkil-piperazina kao modulatori receptora cxcr3